TEMTempus AI, Inc.
The schedule
- Mon19Oct
The HLTH conference will provide visibility into the company's AI capabilities and potential partnerships in the healthcare space, which could influence investor sentiment and short-term price action.
- Tue3Nov
The Q3 earnings release will test the company's ability to deliver on its AI-driven healthcare analytics platform, with a focus on revenue growth and margin expansion. The outcome will be critical for validating the recent acquisition of Personalis and its integration into the core business.
- Thu12Nov
The ASCO 2027 Annual Meeting will provide an opportunity for the company to showcase its AI-driven oncology solutions and potential collaborations with leading cancer research institutions, which could influence investor sentiment and short-term price action.
- Tue15Dec
The CMS reimbursement policy update will test the company's ability to adapt its AI models to evolving regulatory frameworks, which could impact revenue recognition and operational efficiency.
- Tue9Feb
The Q4 earnings release will provide a comprehensive view of the company's year-end performance, including the full impact of the Personalis acquisition and progress on AI-driven healthcare solutions.
- Tue4May
The Q1 earnings release will provide insight into the company's ability to sustain growth in the AI healthcare space, with a focus on new product launches and customer adoption.
- Tue5Oct
Tempus AI Inc Stock (TEM) is expected to close up by 9.03% on October 5, driven by positive sentiment around its AI-driven healthcare solutions and recent strategic partnerships.
Past
- Wed19Aug
Actual outcome: Bull
Tempus AI's acquisition of Personalis for $1.5 billion drove a significant price surge, as the deal signaled strong growth potential and expanded the company's capabilities in precision medicine. The acquisition is viewed as a strategic move to enhance its offerings in oncology and diagnostics, which directly impacted investor sentiment and led to the 23.92% return over the ultra-short horizon. [Market retrospective · Ultra-Short (1–5 days)] Missed anticipation: +23.9% from 2026-08-18 to 2026-08-20 (~5.5σ vs typical 1d vol). Target evaluation date 2026-08-24 (not yet reached as of 2026-08-20). Confidence 95%. [Market retrospective · Ultra-Short (1–5 days)] Updated observation 2026-08-21: +23.9% from 2026-08-18 (~5.5σ). Target evaluation date 2026-08-24 (not yet reached as of 2026-08-21). [Market retrospective · Ultra-Short (1–5 days)] Updated observation 2026-08-24: +23.9% from 2026-08-18 (~5.5σ). Target date 2026-08-24 reached; move through 2026-08-24 observed. [Market retrospective · Ultra-Short (1–5 days)] Updated observation 2026-09-07: +23.9% from 2026-08-18 (~5.5σ). Target date 2026-08-24 reached; move through 2026-09-07 observed. [Market retrospective · Ultra-Short (1–5 days)] Updated observation 2026-09-08: +23.9% from 2026-08-18 (~5.5σ). Target date 2026-08-24 reached; move through 2026-09-08 observed. [Market retrospective · Ultra-Short (1–5 days)] Updated observation 2026-09-08: +23.9% from 2026-08-18 (~5.5σ). Target date 2026-08-24 reached; move through 2026-09-08 observed. [Market retrospective · Ultra-Short (1–5 days)] Updated observation 2026-09-09: +23.9% from 2026-08-18 (~5.5σ). Target date 2026-08-24 reached; move through 2026-09-09 observed. [Market retrospective · Ultra-Short (1–5 days)] Updated observation 2026-09-10: +23.9% from 2026-08-18 (~5.5σ). Target date 2026-08-24 reached; move through 2026-09-10 observed. [Market retrospective · Ultra-Short (1–5 days)] Updated observation 2026-09-10: +23.9% from 2026-08-18 (~5.5σ). Target date 2026-08-24 reached; move through 2026-09-10 observed. [Market retrospective · Ultra-Short (1–5 days)] Updated observation 2026-09-14: +23.9% from 2026-08-18 (~5.5σ). Target date 2026-08-24 reached; move through 2026-09-14 observed.
Tempus AI's acquisition of Personalis for $1.5 billion drove a significant price surge, as the deal signaled strong growth potential and expanded the company's capabilities in precision medicine. The acquisition is viewed as a strategic move to enhance its offerings in oncology and diagnostics, which directly impacted investor sentiment and led to the 23.92% return over the ultra-short horizon. [Market retrospective · Ultra-Short (1–5 days)] Missed anticipation: +23.9% from 2026-08-18 to 2026-08-20 (~5.5σ vs typical 1d vol). Target evaluation date 2026-08-24 (not yet reached as of 2026-08-20). Confidence 95%. [Market retrospective · Ultra-Short (1–5 days)] Updated observation 2026-08-21: +23.9% from 2026-08-18 (~5.5σ). Target evaluation date 2026-08-24 (not yet reached as of 2026-08-21). [Market retrospective · Ultra-Short (1–5 days)] Updated observation 2026-08-24: +23.9% from 2026-08-18 (~5.5σ). Target date 2026-08-24 reached; move through 2026-08-24 observed. [Market retrospective · Ultra-Short (1–5 days)] Updated observation 2026-09-07: +23.9% from 2026-08-18 (~5.5σ). Target date 2026-08-24 reached; move through 2026-09-07 observed. [Market retrospective · Ultra-Short (1–5 days)] Updated observation 2026-09-08: +23.9% from 2026-08-18 (~5.5σ). Target date 2026-08-24 reached; move through 2026-09-08 observed. [Market retrospective · Ultra-Short (1–5 days)] Updated observation 2026-09-08: +23.9% from 2026-08-18 (~5.5σ). Target date 2026-08-24 reached; move through 2026-09-08 observed. [Market retrospective · Ultra-Short (1–5 days)] Updated observation 2026-09-09: +23.9% from 2026-08-18 (~5.5σ). Target date 2026-08-24 reached; move through 2026-09-09 observed. [Market retrospective · Ultra-Short (1–5 days)] Updated observation 2026-09-10: +23.9% from 2026-08-18 (~5.5σ). Target date 2026-08-24 reached; move through 2026-09-10 observed. [Market retrospective · Ultra-Short (1–5 days)] Updated observation 2026-09-10: +23.9% from 2026-08-18 (~5.5σ). Target date 2026-08-24 reached; move through 2026-09-10 observed. [Market retrospective · Ultra-Short (1–5 days)] Updated observation 2026-09-14: +23.9% from 2026-08-18 (~5.5σ). Target date 2026-08-24 reached; move through 2026-09-14 observed.
